Stargardt Disease clinical trials at UCSF
2 in progress, 1 open to eligible people
Stargardt disease is an inherited eye disorder that can cause vision decline. UCSF is conducting a trial to study the effects of an experimental drug on those with Stargardt's gene. This research will gather data on the drug's safety and processing in the body.
ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)
open to eligible people ages 18 years and up
This study is an open-label, single ascending dose clinical trial in participants who have ABCA4-related retinopathies. This is the first-in-human clinical trial in which ACDN-01 will be evaluated for safety, tolerability, and preliminary efficacy following a single subretinal injection of ACDN-01.
San Francisco, California and other locations
Tinlarebant in Subjects With Stargardt Disease
Sorry, not currently recruiting here
The goal of this clinical trial is to evaluate the safety, tolerability, and efficacy of tinlarebant in subjects with Stargardt Disease
San Francisco, California and other locations
Our lead scientists for Stargardt Disease research studies include Jacque Duncan.
Last updated: